Ceftobiprole found to be Safe for the Treatment of Pneumonia
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Ceftobiprole, an advanced-generation broad-spectrum intravenous (IV) cephalosporin, is an important and well-tolerated medication for adults with hospital-acquired pneumonia (HAP) or community-acquired pneumonia (CAP), as well as children.

Ceftobiprole versus standard-of-care (SoC) IV cephalosporin therapies (ceftazidime or ceftriaxone), with or without vancomycin, were randomized (2:1) in patients with HAP or CAP who needed hospitalization. Patients that show clinical progress after at least 3 days of IV treatment may be moved to an oral antibiotic for a period of 7 days of treatment.

--Overall, 138 patients were randomized to ceftobiprole (n = 94) or a SoC cephalosporin (n = 44).

--Median time to oral switch was 6.0 days in the ceftobiprole group and 8.0 days in the SoC cephalosporin group.

--While on IV therapy, adverse events and treatment-related adverse events were reported by 20.2% and 8.5% of ceftobiprole-treated patients and 18.2% and 0% of SoC cephalosporin-treated patients.

--Early clinical response rates at day 4 in the intention-to-treat population were 95.7% and 93.2% in the ceftobiprole and comparator groups, and clinical cure rates at the test-of-cure visit were 90.4% and 97.7%, respectively.

Conclusively, Ceftobiprole was well tolerated and, in this small phase 3 study, demonstrated similar efficacy to SoC cephalosporins in pediatric patients with HAP or CAP requiring hospitalization.

Source: https://journals.lww.com/pidj/Fulltext/2021/06000/A_Phase_3,_Randomized,_Investigator_blinded_Trial.13.aspx